Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Summit Therapeutics Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while Summit Therapeutics Inc trades at $15.03 (market cap $11.84B). The key difference: Summit Therapeutics Inc is far larger — about 7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AMC | SMMT | |
|---|---|---|
Market Cap | $1.69B | $11.84B |
Sector | Media | Health |
52-Week High | $3.54 | $29.32 |
52-Week Low | $0.95 | $13.05 |
Enterprise Value | $9.28B | $11.26B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
Summit Therapeutics (SMMT) trades at $15.25, down 1.49% today, with technical indicators showing bearish momentum despite recent positive clinical trial results for its lead oncology drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while cash flow trends show increasing operational cash burn. Analyst consensus remains bullish with 14 buy ratings and a $15.57 price target, reflecting optimism around the drug's potential despite financial challenges.
SMMT presents a high-risk, high-reward opportunity centered on binary clinical outcomes. Near-term catalysts include FDA review of ivonescimab, but substantial financial losses and dependence on a single asset create significant volatility. The stock's outlook hinges entirely on successful drug commercialization, with current valuations disconnected from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
